Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry-Reference-Cited by-同舟云学术

Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

Published:2022-09-09 Issue:1 Volume:37 Page:57-64
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Muniesa Cristina¹²^ORCID,Gallardo Fernando³,García‐Doval Ignacio⁴^ORCID,Estrach M. Teresa⁵,Combalia Andrea⁵,Morillo‐Andújar Mercedes⁶,De la Cruz‐Vicente Fátima⁷,Machan Salma⁸^ORCID,Moya‐Martínez Cristina⁸^ORCID,Rovira Roger³,Sanchez‐Gonzalez Blanca⁹,Acebo Elvira¹⁰,Amutio Elena¹¹,Peñate Yeray¹²^ORCID,Losada‐Castillo Maria del Carmen¹³,García‐Muret M. Pilar¹⁴,Iznardo Helena¹⁴^ORCID,Román‐Curto Concepción¹⁵,Cañueto Javier¹⁵^ORCID,Fernández‐de‐Misa Ricardo¹⁶^ORCID,Flórez Ángeles¹⁷,Izu Rosa María¹⁸,Torres‐Navarro Ignacio¹⁹,Zayas Ana²⁰,Pérez‐Paredes Gema²¹,Blanes Mar²²,Yanguas J. Ignacio²³,Pérez‐Ferriols Amparo²⁴,Callejas‐Charavia Marta²⁵,Ortiz‐Romero Pablo Luis²⁶,Pérez‐Gil Amalia²⁷,Prieto‐Torres Lucia²⁸,González‐Barca Eva²⁹,Servitje Octavio¹^ORCID

Affiliation:

1. Department of Dermatology Hospital Universitari de Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet de Llobregat Barcelona Spain

2. Department of Dermatology Hospital de Viladecans Viladecans, Barcelona Spain

3. Department of Dermatology Hospital del Mar, IMAS‐IMIM Barcelona Spain

4. Research Unit Fundación Piel Sana AEDV Madrid Spain

5. Department of Dermatology, Hospital Clínic Universitat de Barcelona, IDIBAPS Barcelona Spain

6. Department of Dermatology Hospital Universitario Vírgen del Rocío Sevilla Spain

7. Department of Hematology Hospital Universitario Vírgen del Rocío. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla Sevilla Spain

8. Department of Dermatology Fundación Jiménez Díaz Madrid Spain

9. Department of Hematology Hospital del Mar, IMAS‐IMIM Barcelona Spain

10. Department of Dermatology Hospital Universitario de Cruces Barakaldo Bizkaia Spain

11. Department of Hematology Hospital Universitario de Cruces Barakaldo Bizkaia Spain

12. Department of Dermatology Complejo Hospitalario Universitario Insular Materno‐Infantil, Las Palmas de Gran Canaria, Las Palmas Spain

13. Department of Hematology Complejo Hospitalario Universitario Insular Materno‐Infantil, Las Palmas de Gran Canaria, Las Palmas Spain

14. Department of Dermatology Hospital Santa Creu i Sant Pau Barcelona Spain

15. Department of Dermatology Hospital Universitario de Salamanca Salamanca Spain

16. Department of Dermatology Hospital Universitario Nuestra Señora de Candelaria Santa Cruz de Tenerife Spain

17. Department of Dermatology Complejo Hospitalario Universitario de Pontevedra Pontevedra Spain

18. Department of Dermatology Hospital de Basurto Bilbao Spain

19. Department of Dermatology Hospital Universitario La Fe Valencia Spain

20. Department of Dermatology Hospital Universitario Dr Peset Valencia Spain

21. Department of Dermatology Hospital Universitario Marqués de Valdecilla Santander Spain

22. Department of Dermatology Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) Alicante Spain

23. Department of Dermatology Hospital Universitario de Navarra Pamplona, Navarra Spain

24. Department of Dermatology Hospital General Universitario de Valencia Valencia Spain

25. Department of Hematology Hospital Príncipe de Asturias Madrid Spain

26. Department of Dermatology Hospital Universitario 12 de Octubre, Institute I+12 Research Institute, Universidad Complutense Madrid Spain

27. Department of Dermatology Hospital Universitario Vírgen de Valme Sevilla Spain

28. Department of Dermatology Hospital Universitario Lozano Blesa Zaragoza Spain

29. Department of Hematology Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, L'Hospitalet de LLobregat Barcelona Spain

Funder

Kyowa Hakko Kirin

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18563

Reference20 articles.

1. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

2. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

3. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis

4. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas

5. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preliminary Experience in Ultra-High Frequency Ultrasound Assessment of Cutaneous Primary Lymphomas: An Innovative Classification;Cancers;2024-07-04

2. Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30‐positive cutaneous T‐cell lymphoma;The Journal of Dermatology;2024-06-14

3. Systemic treatments with monoclonal antibodies in mycosis fungoides and Sézary syndrome;Dermatology Reports;2024-05-07

4. Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin;Journal of Clinical Medicine;2024-01-31

5. CD30 in Cutaneous Pathology;The American Journal of Dermatopathology;2023-09